Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis RXi Pharmaceuticals Corp RXII

Healthcare Biotechnology
"RXi Pharmaceuticals Corp is a clinical-stage RNAi company developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which address significant unmet medical needs."

Opinion & Analysis (NDAQ:RXII)

    Coverage Initiated on 'True Original' Using RNAi to Enhance Cancer Immunotherapy

    Streetwise Reports July 11, 2018

    Biotech with transformative RNAi delivery system set for multiple catalysts by year-end

    The Life Sciences Report October 5, 2017

    RXi Pharmaceuticals expands collaboration with Norwegian cancer firm; gears up for 2017 milestones

    The Life Sciences Report June 8, 2017

    RXi Pharmaceuticals receives Japanese patent for RNAi Platform

    The Life Sciences Report April 13, 2017

    RXi-MirImmune merger aims to unlock value through groundbreaking technology

    The Life Sciences Report February 22, 2017

    Agreement launches RXi Pharmaceuticals into dynamic immuno-oncology arena

    The Life Sciences Report November 15, 2016